How Can Post-Translational Modifications Reveal the Truth of Diseases
In life sciences research, proteins serve as the direct functional units responsible for executing diverse and essential biological processes. However, a protein's functional state is not solely determined by its amino acid sequence—it is also intricately regulated by post-translational modifications (PTMs). PTMs refer to chemical alterations, either enzymatic or non-enzymatic, that occur on specific amino acid residues after protein biosynthesis. Common types of PTMs include phosphorylation, acetylation, methylation, ubiquitination, and glycosylation. These modifications modulate protein structure, stability, activity, and interactions, thereby playing pivotal roles in key cellular processes such as signal transduction, metabolic regulation, and immune recognition. In recent years, mounting evidence has demonstrated a strong association between aberrant PTMs and the onset and progression of numerous diseases.
Why Are PTMs Crucial Clues for Understanding Disease Mechanisms?
Unlike DNA and RNA, proteins directly participate in biological functions, and PTMs introduce an additional, highly dynamic layer of regulation upon them. A single protein often harbors multiple potential modification sites, with different modifications potentially exhibiting synergistic or antagonistic interactions, forming a complex and context-dependent "modification code." This reversible and adaptive regulatory system enables cells to promptly respond to environmental cues.
Under physiological conditions, PTMs maintain cellular homeostasis. However, dysregulation, such as altered activity of key modifying enzymes, mutations at modification sites, or disruptions in regulatory networks—can impair protein function and trigger pathological consequences. For instance, aberrant modifications may lead to protein aggregation and structural disruptions, absence of modifications can hinder signaling cascades, and excessive modifications might activate nonspecific transcriptional programs. These molecular perturbations are frequently implicated in the pathogenesis of cancers, neurodegenerative disorders, and autoimmune diseases.
From PTM Landscapes to Disease Signals: How Can They Be Deciphered?
To elucidate the connections between PTMs and disease, researchers leverage high-throughput omics technologies, particularly mass spectrometry-based proteomics and PTM-omics. These platforms enable the large-scale identification and quantification of diverse PTM events, facilitating their integration with disease phenotypes, signaling pathways, and clinical indicators.
Investigations typically begin with constructing PTM maps that compare modification patterns under healthy and diseased conditions. By profiling alterations in modification sites across different states, researchers can pinpoint disease-associated PTM events. Subsequent integration with bioinformatics tools—such as functional annotation and pathway enrichment analysis—helps uncover the affected biological processes, including cell cycle regulation, oxidative stress responses, and metabolic reprogramming. These insights support the development of “modification–function–phenotype” frameworks that bridge molecular changes to disease mechanisms.
Potential Applications of PTMs in Disease Research
With the advancement of analytical technologies, research on post-translational modifications (PTMs) is gradually moving from basic science toward clinical application, revealing promising potentials in the following aspects:
1. Discovery of Disease Biomarkers
Due to their high temporal and spatial specificity, PTMs represent ideal candidates for biomarker discovery. Detection of specifically modified proteins in body fluids enables early diagnosis and accurate subtyping of diseases. For instance, in cancer studies, panels of differentially modified proteins have been employed for molecular subtyping or to predict therapeutic responses.
2. Identification of Drug Targets and Elucidation of Mechanisms of Action
Many targeted therapies are designed to inhibit key enzymes responsible for PTMs, such as kinases, acetyltransferases, and ubiquitin ligases. Investigating the substrate profiles and regulatory networks of these enzymes can deepen our understanding of their biological functions, thereby guiding the development of highly selective inhibitors. Moreover, comparative analysis of PTM patterns before and after drug treatment can provide insights into mechanisms of action as well as potential drug resistance mechanisms.
3. Personalized Medicine and Precision Treatment
Inter-individual variations in genetic background and metabolic status can lead to distinct PTM profiles even within the same disease. By constructing patient-specific PTM network maps, it becomes feasible to support personalized therapeutic strategies, including the selection of targeted treatments, prediction of treatment efficacy, and assessment of adverse reaction risks.
As a core mechanism in the regulation of protein function, post-translational modifications are emerging as a crucial window into the molecular underpinnings of disease. By systematically investigating dynamic PTM changes and their associated signaling networks, researchers gain more precise insights into disease pathogenesis and access a rich source of molecular information to support innovative approaches to diagnosis and therapy. In this rapidly evolving field, the choice of analytical tools and the optimization of experimental workflows are critical. MtoZ Biolabs specializes in high-resolution mass spectrometry platforms and comprehensive proteomics solutions, providing high-quality, high-throughput PTM proteome analysis services to support scientific discovery and accelerate the efficient translation of basic research into clinical applications.
MtoZ Biolabs, an integrated chromatography and mass spectrometry (MS) services provider.
Related Services
How to order?
